China Fund News reporter Li Zhi
Yaben Chemical, a big bull stock that once rose 4 times, was 44% lashing out after the Spring Festival.
On February 11, Yaben Chemical fell again by 13.07%, and at one point fell to 17% intraday. As of the close, the stock was trading at $15.3, with a total market capitalization of $14.7 billion.
44% plunge in 5 trading days
Due to abnormal stock price fluctuations, Yaben Chemical suspended trading from January 17 and resumed trading at the opening of the market on February 7. However, on the first trading day after the Spring Festival, that is, on February 7, Yaben Chemical opened directly and stopped, opening a plunge mode. On February 8, Yaben Chemical fell again by 17.66%. After just easing on February 9, it fell for two consecutive days on February 10 and 11.
That is to say, only 5 trading days after the holiday, Yaben Chemical fell by 44% cumulatively, and the market value shrank by 11.6 billion yuan. The former 4 times big bull stock has become one of the worst stocks in the year of the A-share tiger.
Funds fled one after another
With the extinguishing of the concept of new crown oral medicine, various funds have fled. According to the trading public information released by the Shanghai and Shenzhen Exchanges on February 8, Yaben Chemical was on the Dragon and Tiger List due to the deviation of the daily price decline of -17.66% and the price decline during the abnormal period reached -36.58%. This is the third time in the last 5 trading days to make the list.
The list shows that the total net sale of the top five seats sold was 236.8122 million yuan, and there were top floating funds appearing in it, and the sales department of Industrial Securities Shaanxi Branch sold 113 million yuan.
The total net purchase of the top five seats was 96.7461 million yuan, while the second business department of The East Ring Road of Orient Wealth Securities Lhasa occupied a seat, with a net purchase of 17.3787 million yuan on the day.
Yaben Chemicals once soared 440%
The actual controller reduced his holdings at a high level
Due to the impact of the concept of new crown oral drugs, Yaben Chemical's stock price has soared continuously since November last year, from 5 yuan / share all the way to 27.32 yuan / share, during which the cumulative increase reached 440%, once called a demon.
It is worth noting that after the sharp rise in the stock price, Wang Xinya, one of the actual controllers of Yaben Chemical, reduced his holding of 19 million shares through block trading on November 30, 2021, a proportion of 1.97%, with a reduction amount of about 138 million yuan.
Yaben Chemicals clarifies again:
No cooperation agreement was signed with Pfizer
Due to the abnormal fluctuations in the company's stock trading, Yaben Chemical frequently received letters of concern and repeatedly issued announcements on suspension verification.
In the letter of concern, the Shenzhen Stock Exchange asked Yaben Chemical to explain whether the company violated fair information disclosure and hyped up the stock price through interaction. At the same time, it is explained whether it is suspected of using media information about the possible indirect use of carolong anhydride by Pfizer's new crown oral drug to raise investor expectations and cooperate with the speculation of the company's stock price.
On January 28, Yaben Chemical replied to the Shenzhen Stock Exchange's letter of concern, saying that as of now, the company mainly supplies carophenic anhydride and its derivatives to 6 customers. As of January 27, the company's caronic anhydride and its derivatives had an order amount of 62.1506 million yuan in hand, and the sales volume for the month was 23.4116 million yuan.
It is worth noting that Yaben Chemical changed its words this time, and said that carolongic anhydride and its derivative products are antiviral drug intermediates, and customers may be used for research and development, synthesis or trade of downstream products after procurement. Carolongic anhydride and its derivatives refer to compounds, not specifically products produced by the Company, and it is not possible to determine that the Company's production of carolongic anhydride and its derivatives can be used to synthesize Pfizer's ORAL drugs.
Regarding the cooperation between Pfizer, Yaben Chemical once again said that the company did not sign a cooperation agreement with Pfizer, did not supply carolongic anhydride products to Pfizer, and did not provide Pfizer with any quality standards for the procurement of raw materials for the front-end of the new crown oral drug. The company repeatedly tried to communicate with customers about the end use of its purchasing company caromous anhydride and its derivatives, but the customer refused.
In terms of expansion matters, Yaben Chemical said that the expansion of carolongic anhydride and its derivatives has not yet been decided, and there is still great uncertainty in the final decision. As the downstream market situation of caronic anhydride and its derivatives becomes clear, the company will make a planning and prudent decision on whether to expand production.
Previously, Yaben Chemical disclosed the 2021 annual performance forecast, the company expects the net profit attributable to the shareholders of the listed company in 2021 to be 180 million yuan to 200 million yuan, an increase of 11.79% -24.21% year-on-year, and the net profit after deducting non-recurring gains and losses is expected to be 142 million yuan to 162 million yuan.
However, after a year, the new crown testing sector performed poorly, and on February 11, the new crown testing index fell by 4.68%. In terms of individual stocks, Wantai Biological, Jiuan Medical, Heatscape Biological, etc. all fell by more than 9%, in addition to Meikang Biological, Oriental Biological, Saili Medical, etc. all fell.
Edit: Joey
Copyright Notice